



Revolutionizing Clinical Trials for Alzheimer's: An International Perspective





Welcome & introduction

**Pierre Meulien
Executive Director
Innovative Medicines Initiative**



IMAGINE


The panel

- **Pierre Meulien | Innovative Medicines Initiative**
- **Simon Lovestone | University of Oxford**
- **Paul Stoffels | Johnson & Johnson**
- **Heather Snyder | Alzheimer's Association**



IMAGINE

People living with dementia (millions)





IMAGINE

1500



IMAGINE

£ £ £

€ € €

\$ \$ \$

¥ ¥ ¥



IMAGINE

nada

0

zilch

nothing

nix



IMAGINE

Because...

- the therapeutic targets may have been incorrect
- treatments may have been given too late in the disease process
- the current clinical trial process for developing proof of concept is inefficient

IMAGINE

WE NEED TO DO THINGS DIFFERENTLY

- Focus on prevention, before symptoms appear
- Use adaptive trial design
- Initiatives underway in Europe and US

IMAGINE

THANK YOU!

Pierre Meulien

Executive Director, Innovative Medicines Initiative

www.imi.europa.eu | @IMI_JU

